Efficacy of percutaneous renal artery intervention and drug therapy in patients with atherosclerotic renal arterial stenosis：a Meta-analysis

Fan-hua MENG,Yuan-yuan HAN,Hao WANG,Yi-tong MA,Xiang MA

DOI: https://doi.org/10.3969/j.issn.1674-4055.2015.05.03

2015-01-01

Abstract:Objective To review systematically the clinical efficacy of percutaneous renal artery intervention (PRAI) and drug therapy in patients with atherosclerotic renal arterial stenosis (ARAS).Methods The databases of PubMed, EMbase, Cochrane Library, CMB, CNKI and WanFang Database were retrieved with computer for collecting randomized controlled trials (RCT) about the curative effect of PRAI and drug therapy on ARAS. All selected RCT were screened by 2 reviewers according to inclusion and exclusion criteria. After extracting data and quality evaluation, the RCT were given a Meta-analysis by using RevMan5.3 software provided by Cochrane Collaboration. Resutls There were finally 8 RCT included (2221 cases, 1101 in PRAI group and 1120 in drug group). The results of Meta-analysis showed that systolic blood pressure (SBP) decreased in PRAI group compared with drug group at follow-up end point (WMD=0.95 mmHg, 95%CI: -0.59~2.48,P=0.23), and diastolic blood pressure (DBP) had no statistical difference between 2 groups (WMD=-0.75mmHg, 95%CI: -3.35~1.84,P=0.57). The incidence of renal vessel events had no statistical difference between 2 groups (OR=0.91, 95%CI: 0.73~1.14,P=0.41). The incidence of all-cause mortality (OR=0.89, 95%CI: 0.70~1.13,P=0.35), nonfatal myocardial infarction (OR=1.01, 95%CI: 0.71~1.43, P=0.96), congestive heart failure (OR=0.87, 95%CI: 0.64-1.17,P=0.36) and stroke (OR=0.79, 95%CI: 0.51~1.20, P=0.26) had statistical difference between 2 groups.Conclusion The end point blood pressure, all-cause mortality rate and incidence of major adverse cardiovascular, cerebrovascular and renovascular events cannot be reduced in patients treated with PRAI compared with those treated with drugs only.